Barclays Reiterates Overweight Rating on ANI Pharmaceuticals (ANIP): 'expect a strong recovery here'
Tweet Send to a Friend
Barclays analyst Glen Santangelo reiterated an Overweight rating and $100.00 price target on ANI Pharmaceuticals (NASDAQ: ANIP)The analyst commented, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
